Condition
SARS-CoV-2 (COVID-19) Infection
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06848309Recruiting
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
NCT07387211Not ApplicableCompleted
Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region
NCT07095049Phase 1Active Not RecruitingPrimary
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
NCT04333914Phase 2CompletedPrimary
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Showing all 4 trials